Pim kinase inhibitors in cancer: medicinal chemistry insights into their activity and selectivity

Soraya Alnabulsi1, Enas A Al-Hurani1

  • 1Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, PO Box 3030, Irbid 22110, Jordan.

Drug Discovery Today
|September 24, 2020
PubMed

Insights

Selective inhibition of oncogenic Pim kinases (Pim-1/2/3) offers a promising cancer therapy strategy. Targeting the unique proline-rich hinge region allows for potent and safe Pim kinase inhibitors, advancing cancer drug development.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Pim kinase proteins (Pim-1/2/3) are oncogenic, regulating cell cycle and proliferation via phosphorylation.
  • Pim kinase is a validated chemotherapeutic target, with inhibitors under intensive drug design and development.
  • Existing inhibitors have shown promise in hematological cancers but none have reached clinical approval.

Purpose of the Study:

  • To review the design and development of selective and potent Pim kinase inhibitors.
  • To focus on novel chemotypes and structural features crucial for high potency and selectivity.
  • To explore strategies for inhibiting Pim kinase while preserving other kinase functions and reducing toxicity.

Main Methods:

  • Review of published literature on Pim kinase inhibitor design and development.
  • Analysis of structural features, particularly the proline-rich hinge region, for selective inhibition.
  • Discussion of novel chemotypes and their structure-activity relationships.

Main Results:

  • The proline-rich hinge region of Pim kinases presents a unique opportunity for selective inhibitor design.
  • Novel chemotypes have been developed with improved potency and selectivity profiles.
  • Despite clinical evaluations, challenges remain in bringing Pim kinase inhibitors to market.

Conclusions:

  • Selective Pim kinase inhibition is a viable strategy for cancer therapy.
  • Understanding structural features is key to developing effective and safe Pim inhibitors.
  • Further research into novel chemotypes and clinical translation is warranted.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K